Study:
A Children`s Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (STI571 NSC#716051/IND#55666)
Rationale:
Giving combination chemotherapy before a donor peripheral stem cell transplant
helps stop the growth of cancer cells. It also helps stop the patient`s immune system from
rejecting the donor`s stem cells. When the healthy stem cells from a donor are infused into
the patient they may help the patient`s bone marrow make stem cells, red blood cells, white
blood cells, and platelets.
Purpose:
This phase II trial is studying how well combination chemotherapy with or without
donor peripheral stem cell transplant works in treating children with acute lymphoblastic
leukemia.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Leukemia |
Biological: filgrastim
Drug: asparaginase
Drug: cyclophosphamide
Drug: cyclosporine
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: etoposide
Drug: ifosfamide
Drug: imatinib mesylate
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: pegaspargase
Drug: vincristine sulfate
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Procedure: umbilical cord blood transplantation
Radiation: radiation therapy |
Phase 3 |
Verified by
Children`s Oncology Group
November, 2010
Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00022737
Study Type: Interventional
Study Design: Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-5217
United States
Kirk R. Schultz, MD., Study Chair